Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hallqvist

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|April 22, 2022
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based <sup>177</sup>Lu-DOTATATE treatment of NET patientsAnna Sundlöv, Katarina Sjögreen Gleisner, Jan Tennvall, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trialAndreas Hallqvist, Stefan Bergström, Hedvig Björkestrand, et al.
JTO Clinical and Research Reports|September 10, 2025
Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish CohortElla A Eklund, Sama I Sayin, Jonas Smith Jonsson, et al.
International Journal of Molecular Sciences|March 13, 2024
Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less <i>KRAS</i> and More <i>EGFR</i> Mutations Compared to Advanced AdenocarcinomasJennie Petterson, Dyar Mustafa, Sashidar Bandaru, et al.
Lung Cancer (Amsterdam, Netherlands)|October 12, 2025
Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitorsAnna Lundgren, Susannah Leach, Joanna Kaim, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 8, 2016
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLCJan Nyman, Andreas Hallqvist, Jo-Åsmund Lund, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2019
Intraperitoneal α-Emitting Radioimmunotherapy with <sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose EstimationsAndreas Hallqvist, Karin Bergmark, Tom Bäck, et al.
Frontiers in Oncology|April 28, 2025
Distinct metastatic organotropism shapes prognosis in lung adenocarcinoma with brain metastasisSama I Sayin, Ella A Eklund, Kevin X Ali, et al.
Frontiers in Oncology|February 27, 2023
Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancerNikita Dutta, Anna Rohlin, Ella A Eklund, et al.
Clinical Lung Cancer|June 9, 2023
KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer RegistryJohan Isaksson, Anders Berglund, Karly Louie, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
European Journal of Nuclear Medicine and Molecular Imaging|April 22, 2022
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based <sup>177</sup>Lu-DOTATATE treatment of NET patientsAnna Sundlöv, Katarina Sjögreen Gleisner, Jan Tennvall, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trialAndreas Hallqvist, Stefan Bergström, Hedvig Björkestrand, et al.
JTO Clinical and Research Reports|September 10, 2025
Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish CohortElla A Eklund, Sama I Sayin, Jonas Smith Jonsson, et al.
International Journal of Molecular Sciences|March 13, 2024
Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less <i>KRAS</i> and More <i>EGFR</i> Mutations Compared to Advanced AdenocarcinomasJennie Petterson, Dyar Mustafa, Sashidar Bandaru, et al.
Lung Cancer (Amsterdam, Netherlands)|October 12, 2025
Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitorsAnna Lundgren, Susannah Leach, Joanna Kaim, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 8, 2016
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLCJan Nyman, Andreas Hallqvist, Jo-Åsmund Lund, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2019
Intraperitoneal α-Emitting Radioimmunotherapy with <sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose EstimationsAndreas Hallqvist, Karin Bergmark, Tom Bäck, et al.
Frontiers in Oncology|April 28, 2025
Distinct metastatic organotropism shapes prognosis in lung adenocarcinoma with brain metastasisSama I Sayin, Ella A Eklund, Kevin X Ali, et al.
Frontiers in Oncology|February 27, 2023
Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancerNikita Dutta, Anna Rohlin, Ella A Eklund, et al.
Clinical Lung Cancer|June 9, 2023
KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer RegistryJohan Isaksson, Anders Berglund, Karly Louie, et al.
Pageof 4